Neuroscience News at Yale
Using an innovative technology that enables imaging of two individuals during live and natural conditions, Yale researchers have identified specific brain areas in the dorsal parietal region of the brain associated with the social symptomatology of autism.
- October 27, 2022
A new study led by Yale scientists has identified genetic risk factors associated with habitual heavy drinking.
- October 24, 2022
Researchers from Yale University, and the University of Texas Southwestern Medical Center have been awarded a $12.4 million, five-year grant from the National Institute on Aging of the NIH to deploy their unique research models and expertise in a coordinated fashion to develop a novel course of gerontological research.
- October 21, 2022
The Kavli Institute for Neuroscience is now accepting applications for the 2023 Kavli Postdoctoral Award for Academic Diversity.
- October 20, 2022
Efficacy and Safety of Ketamine vs Electroconvulsive Therapy Among Patients With Major Depressive EpisodeSource: JAMA Psychiatry
Yale researchers Greg Rhee, PhD; John H. Krystal, MD; Gerard Sanacora, MD, PhD; and Samuel Wilkinson, MD, conducted a meta analysis published in JAMA Psychiatry to determine if ketamine is as effective as electroconvulsive therapy in patients with major depressive episode.
- October 19, 2022
A new Yale study of neuron activity in the brain has revised scientists’ understanding of how the brain processes and responds to rewards. Marina Picciotto, PhD, Charles B. G. Murphy Professor of Psychiatry and Professor in the Child Study Center, of Neuroscience and of Pharmacology, is the study’s senior author.
- October 18, 2022
Yale Endocrinology Obesity Medicine is a multidisciplinary program.
- October 14, 2022
Stefania Nicoli, PhD, associate professor at the Yale School of Medicine (YSM) Section of Cardiovascular Medicine and the Department of Genetics, has received the Established Investigator Award from the American Heart Association (AHA).
- October 04, 2022
Newly published research from Yale Pathology substantiates the impact of the drug aducanumab in reducing a plaque that is a defining pathologic feature of Alzheimer’s disease.
- October 03, 2022Source: The Tim Ferriss Show
John H. Krystal, MD, Robert L. McNeil, Jr. Professor of Translational Research and Professor of Psychiatry, of Neuroscience, and of Psychology and Chair of the Yale Department of Psychiatry, recently discussed his groundbreaking research into the drug ketamine on the Tim Ferriss Show.